Randolph Steer - Immunic Independent Director
| IMUX Stock | USD 1.27 0.06 4.96% |
Director
Dr. Randolph C. Steer, M.D., Ph.D., is Independent Director of the company. Dr. Steer was an independent pharmaceutical, biotechnology and medical devices consultant since 1989. Dr. Steer has served as Associate Director of Medical Affairs at Marion Laboratories, a thenpublic pharmaceutical company Medical Director at Ciba Consumer Pharmaceuticals Vice President, Senior Vice President and Member of the Executive Committee at Physicians World Communications Group Chairman, President and Chief Executive Officer of Advanced Therapeutics Communications International, a drug regulatory group serving the U.S., Mexico, Latin America, the Pacific Rim, Europe and Japan Chairman and Chief Executive Officer of Vicus.com, Inc. and President and Chief Operating Officer of Capstone Therapeutics Corporationration, a public biotechnology company since 2005.
| Age | 66 |
| Tenure | 19 years |
| Professional Marks | Ph.D |
| Address | 1200 Avenue of the Americas, New York, NY, United States, 10036 |
| Phone | 332 255 9818 |
| Web | https://imux.com |
Immunic Management Efficiency
The company has return on total asset (ROA) of (0.6813) % which means that it has lost $0.6813 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3128) %, meaning that it created substantial loss on money invested by shareholders. Immunic's management efficiency ratios could be used to measure how well Immunic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.81 in 2024. Return On Capital Employed is likely to rise to -3.19 in 2024. At this time, Immunic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 70.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.7 M in 2024.Management Performance
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.68 |
Immunic Leadership Team
Elected by the shareholders, the Immunic's board of directors comprises two types of representatives: Immunic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunic. The board's role is to monitor Immunic's management team and ensure that shareholders' interests are well served. Immunic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aron Stern, Chief Administrative Officer | ||
| Jorg Neermann, Director | ||
| Andrew Henry, Vice President - Clinical Operations | ||
| Jan Bossche, Director | ||
| Inderpal Singh, General Counsel | ||
| Jessica Breu, Head Communications | ||
| Randolph Steer, Independent Director | ||
| Vincent Ossipow, Director | ||
| MBA MD, Ex Chairman | ||
| Andreas Muehler, Chief Medical Officer | ||
| Tamara Seymour, Interim CFO | ||
| Manfred Groppel, Principal Financial Officer, COO | ||
| JD MBA, Executive Chairman | ||
| Patrick Walsh, Chief Officer | ||
| Phillip Croxford, Independent Director | ||
| Sanjay Patel, CFO | ||
| Glenn CPA, Chief Officer | ||
| Andreas MD, Chief Officer | ||
| Daniel Vitt, President CEO, Director | ||
| Andrea LoewenRodriguez, Vice President - Regulatory Affairs and Quality Assurance | ||
| Richard Murawski, Vice President - Manufacturing | ||
| Hella Kohlhof, Chief Scientific Officer |
Immunic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 68.87 M | ||||
| Shares Outstanding | 89.93 M | ||||
| Shares Owned By Insiders | 7.72 % | ||||
| Shares Owned By Institutions | 58.06 % | ||||
| Number Of Shares Shorted | 3.03 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 4.48 X | ||||
| EBITDA | (99.11 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.